Table 3.
Patient demographics and treatment characteristics
| Characteristic | Number of patients | Number with local recurrence |
|---|---|---|
| Total | 117 (100%) | 4 (3.4%) |
| Margin size | ||
| < 1 mm | 45 (38.5%) | 2 (4.4%) |
| 1–5 mm | 38 (32.5%) | 1 (2.6%) |
| > 5 mm | 26 (22.2%) | 1 (3.8%) |
| No residual tumor | 8 (6.8%) | 0 (0.0%) |
| Biopsy | ||
| Outside institution | 46 (39.3%) | 1 (2.2%) |
| Home institution | 71 (60.7%) | 3 (4.2%) |
| Radiation status | ||
| No radiation | 15 (12.8%) | 0 (0.0%) |
| Postoperative | 30 (25.6%) | 0 (0.0%) |
| Preoperative | 72 (61.5%) | 4 (5.6%) |
| Tumor grade | ||
| 1 | 28 (23.9%) | 1 (3.6%) |
| 2 | 6 (5.1%) | 0 (0.0%) |
| 3–4 | 83 (70.9%) | 3 (3.6%) |
| AJCC stage | ||
| IA | 13 (11.1%) | 0 (0.0%) |
| IB | 4 (3.4%) | 1 (25.0%) |
| IIA | 36 (30.8%) | 1 (2.7%) |
| IIB | 11 (9.4%) | 1 (9.0%) |
| III | 50 (42.7%) | 1 (2.0%) |
| IV | 3 (2.6%) | 0 (0.0%) |
| Metastatic disease | 32 (27.4%) | 2 (6.2%) |
| Dead of disease | 27 (23.1%) | 2 (7.4%) |
AJCC = American Joint Committee on Cancer.